Amelioration of dermal lesions in streptozotocin-induced diabetic rats by aminoguanidine.
As aminoguanidine (AG) is known to prevent non-enzymatic glycosylation in various tissues, we have histologically and biochemically evaluated AG effects on the skin in control, SZ-diabetic and AG-treated (25 mg/kgbw/day, 10w) diabetic rats. HbA1c and plasma glucose levels in diabetic and AG-treated diabetic rats were maintained about two times higher than those in control rats during the 10 weeks of the experiment. Histological findings revealed that the dermis in diabetic rats was thin and edematous, associated with swelling and degeneration of collagen fibers. Necrobiotic changes were seen in the lower dermis. These changes were greatly improved in AG-treated diabetic rats. Skin glucose contents in diabetic and AG-treated diabetic rats were about 10 times higher than those in the controls, whereas there was no difference in the sorbitol contents between three groups. Dry weight of the skin and collagen content was well correlated (r = 0.9044) and collagen represented 78.0 +/- 2.3% of the dry weight. By SDS-PAGE analysis of cyanogen bromide digests it was shown that high molecular weight peptides were increased in diabetic rats, but were decreased in AG-treated diabetic rats. The mean of glycosaminoglycan (GAG) contents of diabetic skin was 54% of that in the controls (1.58 +/- 0.09 vs. 2.94 +/- 0.39 micrograms/mg dry weight, P < 0.0025), which increased significantly in AG-treated diabetic rats (1.75 +/- 0.07 microgram/mg dry weight, P < 0.01 vs. diabetic).(ABSTRACT TRUNCATED AT 250 WORDS)
Bannai
C
C
Department of Endocrinology and Metabolism, University of Tsukuba, Ibaraki, Japan.
Yamazaki
M
M
Matsushima
Y
Y
Kunika
K
K
Itakura
M
M
Okuda
Y
Y
Yamashita
K
K
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D004591:Electrophoresis, Polyacrylamide Gel; D005947:Glucose / Q000032:analysis; D006442:Glycated Hemoglobin / Q000032:analysis; D006025:Glycosaminoglycans / Q000032:analysis; D006146:Guanidines / Q000627:therapeutic use*; D008297:Male; D009336:Necrosis; D010455:Peptides / Q000032:analysis; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012016:Reference Values; D012867:Skin / Q000187:drug effects / Q000473:pathology*; D012871:Skin Diseases / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D013012:Sorbitol / Q000032:analysis; D013739:Testosterone / Q000097:blood
D001786:Blood Glucose; D005947:Glucose; D006442:Glycated Hemoglobin; D006025:Glycosaminoglycans; D006146:Guanidines; D010455:Peptides; D013012:Sorbitol; D013739:Testosterone; C004479:pimagedine